Cantargia AB

CANTA

SE0006371126

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 16:29:39 31/05/2024 BST			5-day change	1st Jan Change
4.8 ^SEK	+11.84%		+35.59%	+28.41%

05-23	Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy	CI
05-21	Transcript : Cantargia AB, Q1 2024 Earnings Call, May 21, 2024

Cantargia AB Elect Magnus Nilsson and Damian Marron as New Board Members

May 26, 2021 at 04:30 pm

Cantargia AB (publ) elect Magnus Nilsson and Damian Marron as new board members.

Latest news about Cantargia AB

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy	05-23	CI
Transcript : Cantargia AB, Q1 2024 Earnings Call, May 21, 2024	05-21
Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	04-17	CI
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	04-10	CI
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer	04-08	CI
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis	04-02	CI
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia	03-27	CI
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis	03-14	CI
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer	03-05	CI
Transcript : Cantargia AB, 2023 Earnings Call, Feb 22, 2024	02-22
Cantargia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22	CI
Cantargia Secures US Approval to Start Patient Recruitment for Pancreatic Cancer Therapy	02-20	MT
Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab	02-20	CI
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy	02-12	CI
Cantargia Reports Phase I Clinical Progress in the CAN10 Project	01-09	CI
Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10	11-24	CI
Cantargia Maintains Patent for Cancer Treatment Amid Withdrawal of Third-party Appeal	11-20	MT
Transcript : Cantargia AB, Q3 2023 Earnings Call, Nov 10, 2023	11-10
Cantargia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Cantargia Seeks SEK59 Million from Share Sale	31/10/23	MT
Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer	27/09/23	CI
Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR	20/09/23	CI
Cantargia's Investigational Blood Cancer Drug Wins $1.1 Million External US Grant	18/09/23	MT
Cantargia AB Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant	18/09/23	CI
Cantargia Gains Orphan Drug Designation in US for Systemic Sclerosis Treatment	06/09/23	MT

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.8 SEK

Average target price

12.67 SEK

Spread / Average Target

+163.89%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CANTARGIA AB	+28.41%	74.45M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	114B
REGENERON PHARMACEUTICALS, INC.	+11.60%	105B
BIONTECH SE	-4.68%	23.83B
ARGENX SE	-0.82%	21.73B
GENMAB A/S	-10.12%	18.1B
WUXI APPTEC CO., LTD.	-42.12%	16.34B
BEIGENE, LTD.	-17.47%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.75B
SAREPTA THERAPEUTICS, INC.	+34.58%	11.76B

Bio Therapeutic Drugs

Cantargia AB

Equities

CANTA

SE0006371126

Biotechnology & Medical Research

Cantargia AB Elect Magnus Nilsson and Damian Marron as New Board Members

Latest news about Cantargia AB

Chart Cantargia AB

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs